Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (1y) (2011 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.13 Bn | 625.38 Bn | 17.26 Bn | -0.91% |
| 2 | AbbVie | 442.39 Bn | 435.82 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 366.26 Bn | 359.12 Bn | 12.21 Bn | -130.72% |
| 4 | Novartis Ag | 266.58 Bn | 258.89 Bn | 11.24 Bn | -15.92% |
| 5 | Pfizer | 159.00 Bn | 147.30 Bn | 10.94 Bn | -108.14% |
| 6 | Sanofi | 52.39 Bn | 45.00 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 8 | Incyte | 25.41 Bn | 20.87 Bn | 1.57 Bn | 38.02% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 13.47% |
| 10 | Neurocrine Biosciences | 15.59 Bn | 15.20 Bn | 935.80 Mn | 30.20% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30.20% |
| Mar 31, 2026 | 2,383.26% |
| Dec 31, 2025 | 50.82% |
| Sep 30, 2025 | 64.24% |
| Jun 30, 2025 | 70.13% |
| Mar 31, 2025 | -81.60% |
| Dec 31, 2024 | -32.01% |
| Sep 30, 2024 | 51.41% |
| Jun 30, 2024 | -34.36% |
| Mar 31, 2024 | 153.10% |
| Dec 31, 2023 | 62.50% |
| Sep 30, 2023 | 18.79% |
| Jun 30, 2023 | 639.15% |
| Mar 31, 2023 | -653.92% |
| Dec 31, 2022 | 1,306.85% |
| Sep 30, 2022 | 200.45% |
| Jun 30, 2022 | -140.83% |
| Mar 31, 2022 | -56.43% |
| Dec 31, 2021 | -102.10% |
| Sep 30, 2021 | 137.30% |